Talk:2β-Propanoyl-3β-(4-tolyl)-tropane

This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:

Pharmacology Low‑importance This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles Low This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about 2β-Propanoyl-3β-(4-tolyl)-tropane. PubMed provides review articles from the past five years (limit to free review articles) The TRIP database provides clinical publications about evidence-based medicine. Other potential sources include: Centre for Reviews and Dissemination and CDC

Might the inverse-reverse to the up/down regulation here according to this from other monoamine reuptake obstructors of the tropane class be caused to adherence of the Hebbian rule in this case in spite of and rather than / in contrast to (potential [my postulating of]) violation of it (Hebbian rule) in the case of the others (what I am asking here is whether any shrewd enough may validate if they in-fact do, the other DARI class drugs/molecules/chemicals)? Might there be a mechanism at work giving pre-synaptic qualities to the main strata/plane of affect which we here focus upon prior to the post-synaptic DARI (if indeed it is)? Nagelfar (talk) 10:56, 20 March 2010 (UTC)[reply]